William D. Waddill

CIK: 0001553338

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)15 (53.6%)

Position reduction

Option Exercises (M)7 (25.0%)

Derivative conversions

Awards (A)6 (21.4%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

PTGX

Protagonist Therapeutics, Inc

Director

ANNX

Annexon, Inc.

Director

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

Director

Discretionary Trading P&L

Holdings

Transaction History (28 total)

PTGX
Protagonist Therapeutics, Inc
Jun 23, 2026
Sale(S)
Direct
9K shares at avg. $117.94$1.1M
PTGX
Protagonist Therapeutics, Inc
Jun 23, 2026
Exercise(M)
Direct
9K shares at avg. $16.54$149K
ANNX
Annexon, Inc.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
65K shares-
PTGX
Protagonist Therapeutics, Inc
Jun 10, 2026
Exercise(M)
Direct
3K shares at avg. $11.80$35K
PTGX
Protagonist Therapeutics, Inc
Jun 10, 2026
Sale(S)
Direct
9K shares at avg. $107.68$969K
PTGX
Protagonist Therapeutics, Inc
Jun 10, 2026
Exercise(M)
Direct
6K shares at avg. $16.54$99K
PTGX
Protagonist Therapeutics, Inc
May 29, 2026
Sale(S)
Direct
9K shares at avg. $99.64$897K
PTGX
Protagonist Therapeutics, Inc
May 29, 2026
Exercise(M)
Direct
9K shares at avg. $11.80$106K
PTGX
Protagonist Therapeutics, Inc
Feb 6, 2026
Exercise(M)
Direct
20K shares at avg. $8.31$166K
PTGX
Protagonist Therapeutics, Inc
Feb 6, 2026
Sale(S)
Direct
20K shares at avg. $83.68$1.7M
PTGX
Protagonist Therapeutics, Inc
Jan 2, 2026
Award(A)
Direct
2.7K shares-
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
500 shares at avg. $68.53$34K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
2.4K shares at avg. $66.66$161K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 19, 2025
Sale(S)
Direct
5.5K shares at avg. $68.01$371K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 16, 2025
Award(A)
Direct
7.8K shares-
PTGX
Protagonist Therapeutics, Inc
Oct 10, 2025
Sale(S)
Direct
4K shares at avg. $69.25$277K
PTGX
Protagonist Therapeutics, Inc
Oct 10, 2025
Exercise(M)
Direct
12K shares at avg. $6.98$84K
PTGX
Protagonist Therapeutics, Inc
Oct 10, 2025
Sale(S)
Direct
8K shares at avg. $87.81$702K
PTGX
Protagonist Therapeutics, Inc
Sep 22, 2025
Sale(S)
Direct
4K shares at avg. $64.25$257K
PTGX
Protagonist Therapeutics, Inc
Aug 27, 2025
Sale(S)
Direct
4K shares at avg. $59.25$237K
ANNX
Annexon, Inc.
Jun 5, 2025
Award(A)
Stock Option (Right to Buy)
Direct
55K shares-
PTGX
Protagonist Therapeutics, Inc
Mar 17, 2025
Sale(S)
Direct
4K shares at avg. $54.25$217K
PTGX
Protagonist Therapeutics, Inc
Jan 2, 2025
Award(A)
Direct
5.1K shares-
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 18, 2024
Award(A)
Direct
16.7K shares at avg. $22.99$385K
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Dec 17, 2024
Sale(S)
Direct
3.7K shares at avg. $22.04$83K

		Type	Shares	Price		Ownership
Jun 23, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	9,000	$117.94	$1,061,460	Direct
Jun 23, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	9,000	$16.54	$148,860	Direct
Jun 11, 2026	ANNX Annexon, Inc.	Award(A) Stock Option (Right to Buy)	65,000	-	-	Direct
Jun 10, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	3,000	$11.80	$35,400	Direct
Jun 10, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	9,000	$107.68	$969,120	Direct
Jun 10, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	6,000	$16.54	$99,240	Direct
May 29, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	9,000	$99.64	$896,760	Direct
May 29, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	9,000	$11.80	$106,200	Direct
Feb 6, 2026	PTGX Protagonist Therapeutics, Inc	Exercise(M)	20,000	$8.31	$166,200	Direct
Feb 6, 2026	PTGX Protagonist Therapeutics, Inc	Sale(S)	20,000	$83.68	$1,673,600	Direct
Jan 2, 2026	PTGX Protagonist Therapeutics, Inc	Award(A)	2,695	-	$0	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	500	$68.53	$34,265	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	2,416	$66.66	$161,051	Direct
Dec 19, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	5,451	$68.01	$370,723	Direct
Dec 16, 2025	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	7,819	-	-	Direct
Oct 10, 2025	PTGX Protagonist Therapeutics, Inc	Sale(S)	4,000	$69.25	$277,000	Direct
Oct 10, 2025	PTGX Protagonist Therapeutics, Inc	Exercise(M)	12,000	$6.98	$83,760	Direct
Oct 10, 2025	PTGX Protagonist Therapeutics, Inc	Sale(S)	8,000	$87.81	$702,480	Direct
Sep 22, 2025	PTGX Protagonist Therapeutics, Inc	Sale(S)	4,000	$64.25	$257,000	Direct
Aug 27, 2025	PTGX Protagonist Therapeutics, Inc	Sale(S)	4,000	$59.25	$237,000	Direct
Jun 5, 2025	ANNX Annexon, Inc.	Award(A) Stock Option (Right to Buy)	55,000	-	-	Direct
Mar 17, 2025	PTGX Protagonist Therapeutics, Inc	Sale(S)	4,000	$54.25	$217,000	Direct
Jan 2, 2025	PTGX Protagonist Therapeutics, Inc	Award(A)	5,130	-	$0	Direct
Dec 18, 2024	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Award(A)	16,733	$22.99	$384,692	Direct
Dec 17, 2024	ARWR ARROWHEAD PHARMACEUTICALS, INC.	Sale(S)	3,747	$22.04	$82,584	Direct

1-25 of 28 transactions

About Waddill William D.

Waddill William D. (SEC CIK 0001553338) files insider reports with the SEC as Director of Protagonist Therapeutics, Inc (PTGX), Director of Annexon, Inc. (ANNX) and Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR).

Signal8 holds 17 ownership filings by Waddill William D., all Form 4s, filed between Sep 12, 2024 and Jun 25, 2026. Those filings report 28 transactions, from Sep 10, 2024 to Jun 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Waddill William D.'s filings is in NEWARK, CA.

Recent filings by Waddill William D.

Jun 23, 2026: Open-market sale of PTGX shares (Form 4, code S).
Jun 23, 2026: Option exercise of PTGX shares (Form 4, code M).
Jun 11, 2026: Grant or award of ANNX derivative securities (Form 4, code A).
Jun 10, 2026: Option exercise of PTGX shares (Form 4, code M).
Jun 10, 2026: Open-market sale of PTGX shares (Form 4, code S).

Other insiders filing for Protagonist Therapeutics, Inc (PTGX)

Ali Asif, Chief Financial Officer
PATEL DINESH V PH D, President and CEO
Giraudo Bryan, Director
MOLINA ARTURO MD, Chief Medical Officer
SELICK HAROLD E, Director
Williams Lewis T, Director

How to read Form 4 transaction codes